Generic drugmakers Hikma and Dr Reddy’s Laboratories have won a surprise victory in a US patent lawsuit that sets up early competition to cardiovascular drug Vascepa, Amarin’s only commercial product.

DUBLIN (AP) — DUBLIN (AP) — Amarin Corp. PLC (AMRN) on Wednesday reported a loss of $7.7 million in its second quarter. On a per-share basis, the Dublin-based company said it had a loss of 37 cents.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The Supreme Court has issued a unanimous decision in Hikma v. Amarin, holding that Amarin did not meet its pleading burden of plausibly alleging that Hikma induced infringement of Amarin’s patents ...

The Supreme Court unanimously sided with generic drugmaker Hikma (HKMPF) and against Amarin Corp. (AMRN) in a case dealing with narrower labels for generic products compared to their brand equivalents ...

Supreme Court justices on Wednesday heard oral arguments over a drug approval pathway that could have implications for the availability of cheaper generic medicines. The case, Hikma v. Amarin, centers ...

Essentially, the company is doing the right thing by trying to milk every dollar out of the only drug it has to sell. But it isn't working from a position of operational strength. The big risk is that ...

Amarin's shares have climbed about 22% over the past year. However, the stock's future looks uncertain at best. While Amarin does have an approved product on the market, Vascepa, a medicine used to ...

Amarin (AMRN) traded ~9% lower on Wednesday after the Irish biotech missed Street forecasts with its Q4 2025 revenue, which indicated that the company’s topline contracted following two consecutive ...

Croatia has for many years been beloved by tourists from Ireland. Dubrovnik and Split are popular destinations for Irish holidaymakers, and Hvar is part of the regular path beaten by interrailers who ...